Introduction
Infection with human immunodeficiency virus (HIV) almost always results in viral persistence. Throughout the incubation period, rapid virus spread and CD4 T-cell turnover systematically damage host immune functions (see review Pantaleo and Fauci 1 ). The prolonged incubation period and the systemic invasion by HIV provide a good opportunity for applying nonconventional interventions such as gene therapy. For HIV gene therapy to be effective, the combination of an efficient delivery vector and a powerful anti-HIV element is necessary.
HIV type 1 (HIV-1)-derived lentiviral vectors can infect both dividing and nondividing cells and efficiently integrate into target cells, thus allowing the therapeutic gene(s) to be expressed permanently. [2] [3] [4] Although lentiviral vectors must meet a higher safety standard in clinical applications, there are certain advantages in applying lentiviral vectors to HIV-infected patients. The patients are HIV positive, and therefore, seroconversion after lentiviral transduction would not present HIV status problem. While the use of self-inactivating (SIN) lentiviral vectors would prevent the spread of the small interfering RNA (siRNA) vectors, the use of non-SIN lentiviral vectors may help mobilize the vectors to other HIV-1 targets and prevent further wild-type HIV-1 replication.
Many different types of anti-HIV genes have been studied including HIV-specific antisense, ribozymes and RNA decoys. 5, 6 The latest development in siRNAmediated gene silencing affords a novel strategy in anti-HIV gene therapy. 7, 8 These include siRNAs targeting host cell receptor CD4 and coreceptors CCR5 or CXCR4 to prevent viral entry, [9] [10] [11] [12] [13] [14] as well as targeting viral genes such as tat, rev, gag and env to inhibit viral replication. [14] [15] [16] [17] [18] [19] For gene therapy to be effective in HIV patients, efficient delivery and long-term stability are necessary. These are known limitations with RNA interference (RNAi) technology. 20, 21 Lentiviral siRNA gene transfer overcomes these problems as demonstrated in several in vitro and transgenic mouse studies. 9, 17, 22, 23 The success of treating HIV infection by siRNA is dependent on high efficiency of viral inhibition to prevent possible escape mutants from the selective pressure of the siRNA inhibition. This will require efficient targeting of highly conserved HIV sequences, or escape mutants are certain to arise. 24 Without welldefined rules, an effective siRNA target site has to be determined empirically ( and Chang, unpublished) . Thus, a rational approach to an effective siRNA gene therapy for HIV infection would be to target multiple highly conserved regions with the hope to identify several effective siRNA target sites.
In this report, we studied siRNA inhibition of HIV-1 in acutely and chronically infected cells using SIN lentiviral insulator vectors carrying siRNAs targeting multiple highly conserved HIV-1 sequences. Efficient inhibition of acute infection (490%) was demonstrated using siRNAs targeting highly conserved gag, pol, int and vpu sequences against different strains of HIV-1. These siRNAs also effectively suppressed HIV-1 replication in chronically infected cells and in primary peripheral blood mononuclear cells (PBMCs). The mechanisms of inhibition are shown to involve specific viral RNA degradation and possible effects on nuclear viral RNAs.
Results siRNAs targeting multiple highly conserved HIV-1 sequences
To identify multiple siRNA target sites in the HIV-1 genome, we searched HIV Sequence Compendium (Kuiken et al (ed), 2001, http://hiv-web.lanl.gov) and identified 11 sites spanning across HIV-1 genome with highly conserved sequences followed by an -AAdinucleotide ( Figure 1a ). These sites include noncoding sequences (U5i and U3i) and coding sequences overlapping gag, pol, int, vpu, env (1st vpui) and nef (see bottom panel of Figure 1a , shown in order of the HIV-1 genome sequence). The U5i, U3i and nefi target all viral RNA species, while the others target either full-length or spliced viral RNAs. The shRNA expression vector was constructed by annealing two synthetic oligonucleotides and cloning into a pBS plasmid adjacent to a human H1 pol III promoter. To generate lentiviral siRNA vectors, the H1-siRNA expression cassette was cut out from the pBS-H1 plasmid and ligated in reverse orientation into the lentiviral SIN insulator vector in front of an internal EF1a-nlacZ reporter gene as shown in Figure 1b . An example of the predicted 21-nucleotide stem-loop siRNA precursor and its corresponding HIV-1 target sequence (2nd poli) is shown at bottom of Figure 1b .
Efficient inhibition of three HIV-1 strains by siRNAs targeting gag, pol, int and vpu
We first used DNA cotransfection to examine the effects of these siRNAs. The pBS siRNA expression plasmid was cotransfected into 293T cells at 20:1 molar ratio (20 siRNA genes to each target gene) with one of the three infectious molecular clones, pNL4-3, p89.6 (p89) and p90CF402.1.8 (p90), and 48 h later, the culture supernatants were collected and assayed for viral reverse transcriptase (RT) activity. The siRNA construct (GFPi) targeting the reporter gene eGFP was included as control. The RT assay demonstrated that five of the 11 HIV-1-specific siRNA constructs, 1st gagi, 2nd poli, 2nd inti and both of the vpui, had marked inhibition effect on HIV-1 NL4-3 and HIV-1 89.6 (X90%, Figure 2a and b) . The HIV-1 90CF402.1.8 , a subtype A/E recombinant, was inhibited by four of the 11 siRNA at 450% efficiency (2nd gagi, 1st poli, 2nd inti and 2nd vpui, Figure 2c ). The U5i and U3i siRNAs, which target noncoding regions of the HIV-1 genome, demonstrated B50% inhibition for HIV-1 NL4-3 and HIV-1 89.6 , but had no effect on HIV-1 90CF402. 1.8 . DNA cotransfection with HIV-2 molecular clone showed no inhibition effect by any of the siRNA constructs (data not shown).
The RT assay measures HIV Pol protein synthesis and activity. To examine the siRNA effects on viral infectivity, we cotransfected 293T cells with pNL4-3 with the HIV-1-specific siRNA constructs or the gfpi control, and 48 h later, the progeny virus was harvested and used to infect CD4-positive MAGI cells, an HIV-1 LTR-b-gal reporter cell line. Quantitative comparison of the progeny virus infectivity in MAGI cells after X-gal staining showed that all of the siRNAs, which targeted viral coding regions, were effective in suppressing HIV-1 infection (80-99%, Figure 2d ) including the nefi construct (B80%), although the latter did not exhibit inhibitory effect by the RT assay. Interestingly, the U5i and U3i, which target noncoding regions in the HIV-1 genome, also exhibited B50% inhibitory effects in the MAGI assay.
Protection from HIV-1-induced cytotoxicity after lentiviral siRNA transduction
The transient transfection assay demonstrated that the siRNA expression plasmids were effective in HIV-1 inhibition. As lentiviral vectors mediate efficient gene delivery and permanent integration into target cells, which overcome problems with transient siRNA gene transfer, we further tested lentiviral vectors expressing these HIV-1-specific siRNAs. Lentivrial siRNA vectors were produced by cotransfection of pNHP, pHEF-VSVG and pTYFsiRNA-EZ (Figure 1b ) into 293T cells, and the vector titer was determined on TE671 cells by bgalactosidase reporter gene assay as described previously. 26 It was predicted that the anti-HIV-1 siRNAs that target gag-pol sequences could also inhibit gag-pol expression from pNHP, the helper construct of the vector system. Therefore, we compared the titers of these different lentiviral siRNA constructs (Figure 3a) . All of the lentiviral siRNA constructs produced viral titers in the range 1-1.5 Â 10 7 /ml (Table 1 ). This result showed that U5i, gagi, poli and inti siRNAs that targeted the helper construct did not significantly affect vector titer. The 2nd poli construct consistently produced lower vector titers than the others.
To test lentiviral siRNA inhibition of HIV-1, we first transduced two human CD4-positive cell lines, CEM-A, an adherent lymphoma cell line, and GHOST hi5 cells; both cell lines are sensitive to M-and T-tropic HIV-1 infection. These two cell lines were first transduced with lentiviral siRNA vectors: gfpi, 2nd gagi or 2nd vpui. The CEM-A and GHOST hi5 cells transduced with lentiviral siRNAs were propagated for 5 days and then challenged with a syncytium-forming HIV-1 (T-tropic HIV-1 NL4-3 and M-tropic HIV-1 NL-AD8 , respectively), and monitored for syncytium formation. The results showed that the gfpi-transduced CEM-A cells formed syncytia in the entire culture (495%) and were killed in 6 days after viral infection. In contrast, the 2nd gagi-transduced CEM-A were partially protected (B30-40% syncytium human T-cell line that has been chronically infected with wild-type HIV-1 (HIV-1 NL4-3 ), which continues to produce high titer HIV-1, was transduced with lentiviral siRNA vectors including gfpi, 2nd poli, 2nd inti, 2nd vpui and a combination of all three siRNA vectors. The chronical MOLT-3 HIV-1 producer cells have been propagated for longer than 9 months and produce HIV-1 continuously (Chang, unpublished) . After lentiviral siRNA transduction, we monitored the transduction efficiency by lacZ reporter gene assay and analyzed viral RT activity in the culture supernatants to determine the siRNA inhibition effects. Figure 4a showed that the efficiency of lentiviral transduction of the MOLT-3 cells was 490% (inset), and all three lentiviral siRNA, 2nd poli, 2nd inti and 2nd vpui, but not gfpi, inhibited HIV-1 replication in the chronic HIV-1 producer cells, and the combination of three HIV-1-specific siRNA vectors displayed the highest inhibition efficiency (495%).
To see if the inhibition was specific to HIV-1 RNA degradation, cytoplasmic and nuclear RNAs were harvested and examined. The quality of the RNA was monitored by EtBr staining of the agarose gel (Figure 4b 
Discussion
The siRNA target sites spanning across gag, pol, int, vpu and vpu/env sequences in the HIV-1 genome studied here are highly conserved among different HIV-1 subtypes as shown by sequence alignment in Figure 6 . It is likely that more conserved and effective target sites will be identified if we screen more siRNAs. The major concern infected HIV-1 culture, a more rigorous test would be to propagate continuously the progeny virus in culture supplemented with uninfected cells. We are currently evaluating the long-term protection effects of these lentiviral siRNAs targeting multiple HIV-1 sites to see if escape mutants will arise. It would also be of great interest to see whether HIV-1 with mutations in these highly conserved domains is viable and become attenuated. HIV-1-derived lentiviral siRNA vectors targeting HIV-1 sequences present a dilemma that an effective siRNA would also suppress vector production. This was indeed observed when we compared the titer of different HIV-1-specific siRNA lentiviral constructs (Figure 3a) . It was apparent that the most effective siRNA vectors (2nd poli and 2nd inti) consistently produced the lowest titer, whereas siRNAs with the target sites deleted from the vector system, such as the two vpui, which inhibited Efficient inhibition of HIV-1 may require high siRNA concentration, because an efficient chain reaction process (transitive RNAi) found in plants and worms does not appear to operate in mammalian cells. 5, 8 In addition to targeting HIV-1, we have observed efficient inhibition of several other genes by using as low as 3-5 MOI of the lentiviral siRNA vectors. High MOI lentiviral transduction (450) induces cytotoxicity possibly due to genome instability (Chang and He, unpublished) . The effective inhibition of HIV-1 by lentiviral siRNA at low MOI (5-10) potentially reduces the risk of saturating cellular RNAi machinery or interfering with chromosomal architecture. 27, 28 This also provides room for the expression of multiple siRNAs in one cell. Thus, inhibition of HIV-1 by multiple lentiviral siRNAs targeting highly conserved sites is a viable gene therapy concept.
Northern analysis of nuclear and cytoplasmic viral RNA of lentiviral siRNA transduced chronic HIV-1 producer cells showed that both nuclear and cytoplasmic viral RNA were downregulated by the lentiviral siRNA (Figure 4b) . Thus, siRNA-associated RNA degradation machinery appears to be nuclear accessible in human lymphocytes. Zeng and Cullen 29 reported that strictly nuclear localized RNAs are not targeted by siRNA, suggesting that siRNA-mediated RNA degradation only functions in the cytoplasm. However, they also observed a 2-fold decrease in nuclear RNA when the target RNA was transported and degraded by siRNA in the cytoplasm. An alternative explanation would be possible siRNA feedback on genome silencing. In yeasts, modification of histone by siRNA-recruited enzymes can result in epigenetic chromatin silencing; 30, 31 however, no such activity has been detected in higher eukaryotic systems. 32 Nevertheless, our results indicate that access to nuclear viral RNA by lentiviral siRNA may not be restricted.
It is worth noting that we consistently observed enhanced viral RT activities when nefi was used to target HIV-1 P86 and HIV-1 P90 . In particular, we observed a consistent 4-fold increase in RT activity when targeting HIV-1 P90 with the nefi vector (Figure 2) . The reason for this is not clear, but it warrants attention that if not selected properly, siRNA may enhance rather than inhibit viral activity. Nevertheless, nefi suppressed HIV-1 NL4-3 progeny virus infectivity by 80% according to the MAGI assay (Figure 2d ). This is also true for U5i and U3i siRNAs, which displayed B50% inhibition effect on viral infectivity. This result suggests that siRNAs targeting RNA viruses may have extended effects on viral infectivity as illustrated here, which could easily be overlooked due to marked inhibition effects on viral gene expression.
By targeting highly conserved HIV-1 sequences and by comparing the effectiveness of individual siRNA on different HIV-1 strains, it is evident that siRNAs effective for one strain may not be effective for another strain of HIV-1. For example, the 1st gagi is more effective than the 2nd gagi in inhibiting HIV-1 NL4-3 and HIV-1 P89.6 , but the 2nd gagi is more effective than the 1st gagi in inhibiting HIV-1 P90 . Likewise, the 2nd poli is more effective than the 1st poli against HIV-1 NL4-3 and HIV-1 P89.6 , but the converse is true when targeting HIV-1 P90 . More consistent effects were found with inti and vpui against all three viral strains. This is probably due to secondary structure differences among different HIV-1 genomes. Thus, the effectiveness of any given siRNA target site in a viral genome must be empirically determined.
Genetic modification of host cells to confer resistance to HIV-1 infection may be viewed as an exotic option to treating this deadly disease. However, with rapid progress in gene delivery and stem cell technologies, this treatment option may soon become possible for patients exhausted with conventional antiretroviral therapy. The intracellular inhibition of viral gene expression and replication, even at a nominal level, may prove to be beneficial to the recovery of host immune cell functions in the prolonged infection course. Lentiviral vectors have demonstrated efficient gene knockin and knockdown in many different cell types. HIV-1-derived vectors may compete with endogenous HIV-1 for virus packaging and spread. To avoid possible adverse effect, the siRNA vector may carry a selfdestruction gene such as herpes thymidine kinase gene. Lentiviral siRNA modification of hematopoietic stem cells restricting multiple highly conserved HIV-1 sequences may offer a long-term solution to chronic HIV-1 infection.
Materials and methods

Tissue culture and HIV-1 molecular clones
The 293T, TE671, MAGI and GHOST hi5 cells were cultured in DMEM with 10% fetal bovine serum (FBS), Figure 5 Lentiviral siRNA inhibition of HIV-1 89.6 infection of primary PBMCs. PBMCs were prepared and treated with 2 mg/ml PHA in PRMI 1640 medium as described in Materials and methods. The cells were transduced with lentiviral siRNA vectors (mock, gfpi, 2nd poli and 2nd vpui) at B20 MOI in a 24-well plate containing 10 mg/ml polybrene and 100 m/ml recombinant human IL-2. After 24 h, the cells were challenged with HIV-1 89.6 at B10 MOI. At 1, 2, 4, 6, 8 and 10 dpc (day postchallenge), the supernatants were harvested for RT assay. After each harvest, the cells were counted and replated to normalize the viral production at per cell base. The RT activity was quantitatively determined by a phosphoimager and plotted. The results are representative of three independent experiments.
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1% glutamine and 1% penicillin-streptomycin. The primary PBMCs were prepared from healthy donors' buffy coat by density-gradient centrifugation using Histo-Hypaque (Sigma) as described previously.
33
GHOST hi5 was derived from HOS cells stably transduced with CD4 and CCR5. CEM-A is a fusion cell clone of CEM and normal PBMC with adherent phenotype susceptible to HIV infection and formation of syncytia. 34 MOLT-3 was purchased from American Type Culture Collection, Rockville, MD, USA. The chronic MOLT-3-HIV-1 NL4-3 producers were generated by infection with low MOI of HIV-1 NL4-3 and continued propagation until the cells recovered from the cytopathic effects and become long-term HIV-1 producers. CEM-A and MOLT-3-HIV-1 NL4-3 cells (Molt-4) were cultured in RPMI 1640 supplemented with 10% FBS, 1% glutamine and 1% penicillin-streptomycin, and PBMCs were cultured in the above RPMI medium supplemented with recombinant human IL-2 (100 mg/ml).
Construction of siRNA plasmids and lentiviraltransducing vectors
The H1 gene was amplified from genomic DNA of 293 cells using a 5 0 primer: (all primer sequences are shown in 5 0 to 3 0 orientation) -CCATGGAATTCGAACGCTG ACGTC-, and a 3 0 primer: -CCTCACCTCAGCCATTG AACTCAC-. The H1 promoter was amplified from the primer: -GCAAGCTTAGATCTGTGGTCTCATACAGAA CTTATAAGATTCCC-. The amplified DNA was digested with EcoRI and HindIII and cloned into pBSKSII to generate pBS-H1. To facilitate directional cloning, two different SfiI cloning sites (A and B) were inserted into XbaI-and HindIII-digested pBS-H1 flanking the H1-promoter region by inserting two linkers with flanking XbaI and HindIII cloning sites using the following four primers: -CTAGAGGCCATTATGGCCG-, -AATTCG GCCATAATGGCCT-, -AGCTTGGCCGCCTCGGCCand -TCGAGGCCGAGGCGGCCA-, to generate pBS-H1-Sfi. The GFP siRNA (gfpi) construct was made by annealing four primers, and the HIV-1 siRNA constructs were made by annealing two primers containing the shRNA sequence with a 9-nucleotide loop -TTCAAGAGA-and flanking EcoRI and HindIII cloning sites, and then cloned into the 3 0 -end of the H1 promoter in the pBS-H1-Sfi plasmid. The siRNA primers are listed below: A lentiviral SIN insulator vector (pTYF-EFnlacZcHS) containing two SfiI (A/B) cloning sites and a 1100 bp stuffer and a chicken HS4 insulator sequence (cHS4) was used to construct all of the lentiviral siRNA vectors. The H1-siRNA fragment was released from the pBS-H1-SfisiRNA plasmid by SfiI digestion and cloned into the reverse lentiviral pTYF-Sfi B/A vector to obtain the siRNA-transducing vector. All of the siRNA sequences were confirmed by DNA sequencing.
DNA transfection and HIV-1 preparation
For the analysis of siRNA effect on HIV-1, 293T cells were cotransfected with pBS-H1-Sfi-siRNA (1.8 mg/well) and HIV-1 DNA (0.2 mg/well) in 12-well plates using Superfect as instructed by the manufacturer (Qiagene). The supernatants were harvested 24 h post-transfection and used for MAGI and RT assays. For the preparation of HIV-1 stocks, 293T cells were transfected with HIV-1 DNA and the supernatants were collected at 12 h intervals for three times 24 h after DNA addition.
Lentiviral vector preparation, titration and transduction
Lentiviral vectors were generated by DNA cotransfection and the virus was concentrated by microfuge centrifugation or filtration as described previously. 26, 35 Briefly, 293T cells were split into six-well plates 17-20 h prior to DNA transfection using Superfect. Different amounts of DNA, including pNHP, pHEFVSVG and pTYF, were mixed with Superfect at 1:2 (DNA:Superfect) ratio and maintained in room temperature for 10 min as instructed by the manufacturer (Qiagene). The DNA was added to 293T cells, and 5 h later, the cells were washed and fed with fresh media. The virus supernatants were collected Lentiviral siRNAs targeting HIV-1 L-J Chang et al after 20, 30 and 45 h for three times. The virus titer was determined on TE671 cells using b-galactosidase reporter gene assay. For lentiviral transduction, the cells were transduced at different MOI in the presence of polybrene (8 mg/ml, Sigma). The target cell transduction efficiency was monitored by reporter gene nlacZ assay as described previously. 26 
HIV-1 infection, RT and MAGI assays
PBMCs were activated with 2 mg/ml PHA in RPMI 1640 medium for 1 day and washed three times before lentiviral siRNA vector transduction (MOI ¼ 10). The siRNA-transduced PBMCs were challenged with wildtype HIV-1 at an MOI of 20 after 24 h. At different time points after HIV-1 challenge, the supernatants were harvested for RT assay. At each harvest, the cells were counted and the same number of viable cells was plated and fed with fresh media. The MOLT-3 cells were transduced with lentiviral-siRNA vectors in RPMI 1640 containing 10 mg/ml polybrene (MOI ¼ 10). To determine virus production, 1 Â 10 5 cells were seeded into 24-well plate in 300 ml/well of fresh RPMI 1640 and after 24 h, the supernatants were harvested for RT assay. The RT assay and MAGI assays were performed as described previously. 33, 36 Cytoplasmic and nuclear RNA analysis
The nuclear and cytoplasmic RNA was harvested as previously described with minor modifications. 35 Briefly, the cells were washed two to three times with cold PBS, and the cell pellets were resuspended in ice-cold 250 ml solution containing 10 mM Tris (pH 7.4), 10 mM NaCl, 3 mM MgCl 2 and 25 ml VRC (20 mM, BRL Life Technologies Invitrogen, La Jolla, CA, USA) and gently lysed by adding 12.5 ml 10% NP40, mixed briefly and sit on ice for 2-3 min. After centrifugation at 800 g for 2 min, the supernatant and the nuclear pellet were separated and the RNA was harvested using TRI Reagent (Molecular Research Center Inc., Cincinnati, OH, USA) as described by the manufacturer. The RNA was analyzed by electrophoresis on a formaldehyde agarose gel, blotted, UV crosslinked and probed with random primed probes (Stratagene, La Jolla, CA, USA) using sequences specific for full-length HIV-1 or b-actin. For rehybridization, the old probe was stripped by boiling the blots in ddH 2 O containing 0.1% SDS for 10 min.
